FDA
-
-
-
-
-
-
-
Leerink Partners Reiterates Market Perform Rating on Century Therapeutics (IPSC)
-
-
-
-
-
-
-
Century Therapeutics (IPSC) Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned
-
-
-
-
-
-
-
Century Therapeutics (IPSC) Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
-
-
-
-
-
-
-
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
-
-
-
-
-
-
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
-
-
-
-
-
-
-
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
-
-
-
-
-
-
-
Century Therapeutics (IPSC) Announces Leadership Changes
-
330,654 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

